Aileron Therapeutics

97 articles about Aileron Therapeutics

• Aileron Therapeutics Announces Acquisition of Lung Therapeutics

  10/31/2023

  Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. ("Lung Tx").

• Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives

  2/21/2023

  Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia (Grade 4) and alopecia.

• Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements

  11/30/2022

  Aileron Therapeutics today announced that it received written notice on November 28, 2022 from The Nasdaq Stock Market noting that Aileron has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), which requires the company to maintain a minimum closing bid price of $1.00 per share.

• Aileron Therapeutics Announces a 1-for-20 Reverse Stock SplitCommon Stock Will Begin Trading on Split-Adjusted Basis on November 11, 2022

  11/10/2022

  Aileron Therapeutics, a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, announced that it will effect a 1-for-20 reverse stock split of its common stock.

• Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

  11/1/2022

  Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives today, reported financial results and business highlights for the third quarter ended September 30, 2022.

• Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference

  10/26/2022

  Aileron Therapeutics presented detailed results from its completed Phase 1 study of ALRN-6924 in healthy volunteers at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics 2022 taking place in Barcelona October 26 – 28, 2022.

• Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage

  9/30/2022

  Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced an oral presentation at the European Society for Dermatological Research (ESDR) Annual Meeting, taking place September 28 – October 1, 2022 in Amsterdam.

• Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference

  9/22/2022

  Aileron Therapeutics today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation and participate in a fireside chat at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:30 p.m. ET in New York, New York.

• Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

  8/15/2022

  Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives today, reported financial results and business highlights for the second quarter ended June 30, 2022.

• Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer

  8/1/2022

  Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today outlined its strategy to strengthen the company’s Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer.

• Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022

  7/8/2022

  Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, announced today that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at the William Blair Biotech Focus Conference 2022, which will be available to view on-demand beginning Monday, July 11, 2022.

• Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

  6/29/2022

  Aileron Therapeutics announced interim data from its Phase 1b chemoprotection trial of patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors.

• 

  Clinical Catch-Up: Amgen, AstraZeneca, Avillion Attack Asthma

  5/23/2022

  Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.

• Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

  5/19/2022

  Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer.

• Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference

  5/17/2022

  Aileron Therapeutics announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 1:30 p.m. ET in Miami, FL.

• Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022

  5/13/2022

  Aileron Therapeutics today announced that it will host a virtual KOL investor event on Thursday, May 19, 2022, at 4:00 pm ET/ 1:00 pm PT.

• Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming SID 2022 Annual Meeting

  5/10/2022

  Aileron Therapeutics announced a late-breaking oral presentation at the upcoming Society for Investigative Dermatology Annual Meeting, which will be held May 18 – 21, 2022 in Portland, Oregon.

• Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

  5/5/2022

  Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives today, reported financial results and business highlights for the first quarter ended March 31, 2022.

• Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations

  4/21/2022

  Aileron Therapeutics announced it has expanded its management team with the appointment of Christopher Zergebel as Vice President of Program Management and Clinical Operations.

• Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

  3/28/2022

  Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2021.